^
Association details:
Biomarker:ALK A348D
Cancer:Leukemia
Drug:Xalkori (crizotinib) (ALK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Therapeutically targetable ALK mutations in leukemia

Excerpt:
The growth of Ba/F3 cells expressing both mutants was highly sensitive to crizotinib, with IC50s of 33 nM for ALK A348D cells and 6 nM for the ALK F856S cells (Figure 2D).
DOI:
https://dx.doi.org/10.1158%2F0008-5472.CAN-14-1576